{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:00:51Z","timestamp":1785477651690,"version":"3.56.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Venous thromboembolism (VTE) represents a common and severe comorbidity in lung cancer patients. This study aimed to characterize the clinical features and independent risk factors associated with VTE in these individuals, and to evaluate the complementary utility of machine learning approaches in enhancing VTE risk stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included lung cancer patients admitted to the Fourth Affiliated Hospital of Anhui Medical University between January 2018 and April 2025. According to imaging findings, patients were categorized into a VTE group and a control group. Clinical characteristics, laboratory parameters, and treatment-related information were retrospectively collected and analyzed. Univariate and multivariable logistic regression analyses were performed to identify factors independently associated with VTE. Additionally, four machine learning models\u2014Ridge-LR, LASSO, random forest (RF), and extreme gradient boosting (XGBoost)\u2014were developed for exploratory purposes. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, calibration metrics (Brier score, calibration slope and intercept, Hosmer-Lemeshow test), and decision curve analysis (DCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 180 patients with lung cancer were included. Elevated D-dimer levels were independently associated with increased VTE risk (OR = 1.084,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.021). Chemotherapy exposure showed an OR of 2.858 (95% CI: 1.081\u20137.555,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.034) for VTE in the 1\u20132 cycle subgroup, although no significant association was observed for higher cycle numbers, suggesting potential confounding. Male sex was independently associated with embolic events occurring outside the lower extremities (OR = 10.83,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.034). Among the machine learning models, RF achieved the highest AUC (0.740), but Ridge-LR demonstrated the best calibration (Hosmer-Lemeshow\n                      <jats:italic>p<\/jats:italic>\n                      = 0.345). LASSO showed the highest net benefit on decision curve analysis, while RF and XGBoost exhibited significant miscalibration (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002 for both). D-dimer (41.3%) and total protein (34.7%) were identified as the most important predictors in the XGBoost model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elevated D-dimer levels measured prior to VTE diagnosis during routine clinical monitoring were independently associated with subsequent VTE, supporting its potential utility as a predictive biomarker for risk stratification in patients with lung cancer. The association between chemotherapy exposure and VTE is likely influenced by selection bias and residual confounding rather than representing a true causal effect. Machine learning models did not demonstrate consistent improvement over logistic regression in discrimination or calibration in this small single-center cohort, suggesting limited added predictive value with the current dataset.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1891648","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:39:02Z","timestamp":1785476342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical risk factors and machine learning for venous thromboembolism in lung cancer: an exploratory single-center study"],"prefix":"10.3389","volume":"13","author":[{"given":"Hongqin","family":"Jia","sequence":"first","affiliation":[{"name":"The Fourth Affiliated Hospital of Anhui Medical University, Chaohu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"The Fourth Affiliated Hospital of Anhui Medical University, Chaohu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Qian","sequence":"additional","affiliation":[{"name":"The Fourth Affiliated Hospital of Anhui Medical University, Chaohu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Anhui Medical University, Chaohu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.5435\/JAAOS-D-17-00763","article-title":"Venous thromboembolism after shoulder arthroplasty and arthroscopy.","volume":"27","author":"Rapp","year":"2019","journal-title":"J Am Acad Orthop Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jjcc.2021.08.026","article-title":"Venous thromboembolism: recent advancement and future perspective.","volume":"79","author":"Yamashita","year":"2022","journal-title":"J Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS).","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12959-025-00795-9","article-title":"Cancer-associated thrombosis (CAT); mechanisms and treatment options.","volume":"23","author":"Alshehri","year":"2025","journal-title":"Thromb J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.thromres.2020.01.010","article-title":"Central venous catheter-related thrombosis in children and adults.","volume":"187","author":"Citla","year":"2020","journal-title":"Thromb Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis.","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA."},{"key":"B8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.lungcan.2012.09.001","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer.","volume":"78","author":"Connolly","year":"2012","journal-title":"Lung Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cllc.2013.06.003","article-title":"Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients.","volume":"14","author":"Connolly","year":"2013","journal-title":"Clin Lung Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.21037\/jtd.2017.11.116","article-title":"Risk factors and prognosis value of venous thromboembolism in patients with advanced non-small cell lung cancer: a case-control study.","volume":"9","author":"Shen","year":"2017","journal-title":"J Thorac Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s12885-020-06930-1","article-title":"Could venous thromboembolism and major bleeding be indicators of lung cancer mortality?","volume":"20","author":"Howlett","year":"2020","journal-title":"BMC Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"E242","DOI":"10.21037\/jtd.2018.03.155","article-title":"Pulmonary embolism concurrent with lung cancer and central emboli predict mortality in patients with lung cancer and pulmonary embolism.","volume":"10","author":"Cha","year":"2018","journal-title":"J Thorac Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.thromres.2018.01.001","article-title":"Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer.","volume":"164","author":"Lyman","year":"2018","journal-title":"Thromb Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1076029620977910","DOI":"10.1177\/1076029620977910","article-title":"Venous thromboembolism in patients with lung cancer.","volume":"26","author":"Suzuki","year":"2020","journal-title":"Clin Appl Thromb Hemost."},{"key":"B15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.20344\/amp.10260","article-title":"Venous and lung thromboembolism in the context of lung cancer: clinical manifestations, risk factors and prognosis.","volume":"32","author":"Maia","year":"2019","journal-title":"Acta Med Port."},{"key":"B16","doi-asserted-by":"publisher","first-page":"407.e","DOI":"10.1016\/j.cllc.2024.02.004","article-title":"Risk of venous thromboembolism in patients with stage III and IV non-small-cell lung cancer: nationwide descriptive cohort study.","volume":"25","author":"Ording","year":"2024","journal-title":"Clin Lung Cancer."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1055\/a-2330-1371","article-title":"Circulating blood biomarkers and risk of venous thromboembolism in cancer patients: a systematic review and meta-analysis.","volume":"124","author":"Roy","year":"2024","journal-title":"Thromb Haemost."},{"key":"B18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"ESMO guidelines committee. venous thromboembolism in cancer patients: ESMO clinical practice guideline.","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.3390\/ijms27041874","article-title":"Cancer-associated thrombosis in patients treated with immune checkpoint inhibitors.","volume":"27","author":"Ilari","year":"2026","journal-title":"Int J Mol Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12959-026-00835-y","article-title":"Pulmonary origin and risk assessment of cancer-associated thrombosis.","volume":"24","author":"Sun","year":"2026","journal-title":"Thromb J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"103244","DOI":"10.1016\/j.rpth.2025.103244","article-title":"RIETE investigators. comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETE.","volume":"9","author":"Monreal","year":"2025","journal-title":"Res Pract Thromb Haemost."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.3390\/ijms27052515","article-title":"Sex differences in cancer-associated thrombosis.","volume":"27","author":"Giachi","year":"2026","journal-title":"Int J Mol Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1044\/2023_JSLHR-23-00273","article-title":"Toward generalizable machine learning models in speech, language, and hearing sciences: estimating sample size and reducing overfitting.","volume":"67","author":"Ghasemzadeh","year":"2024","journal-title":"J Speech Lang Hear Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e048008","DOI":"10.1136\/bmjopen-2020-048008","article-title":"Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence.","volume":"11","author":"Collins","year":"2021","journal-title":"BMJ Open."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1891648\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:39:03Z","timestamp":1785476343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1891648\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":24,"alternative-id":["10.3389\/fmed.2026.1891648"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1891648","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1891648"}}